Genmab A/S (NASDAQ:GMAB) & Sutro Biopharma (NASDAQ:STRO) Critical Contrast

Sutro Biopharma (NASDAQ:STRO) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Sutro Biopharma and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-344.22%	N/A	-76.33%
Genmab A/S	16.97%	13.67%	6.42%

Analyst Ratings

This is a summary of recent ratings for Sutro Biopharma and Genmab A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1	0	10	2	3.00
Genmab A/S	0	1	10	1	3.00

Sutro Biopharma currently has a consensus target price of $49.60, indicating a potential upside of 405.09%. Genmab A/S has a consensus target price of $53.50, indicating a potential upside of 4.15%. Given Sutro Biopharma’s higher probable upside, research analysts plainly believe Sutro Biopharma is more favorable than Genmab A/S.

Valuation & Earnings

This table compares Sutro Biopharma and Genmab A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$45.70 million	3.56	-$191.09 million	($11.97)	-0.82
Genmab A/S	$3.72 billion	8.62	$963.00 million	$1.17	43.91

Genmab A/S has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Sutro Biopharma has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Summary

Genmab A/S beats Sutro Biopharma on 8 of the 13 factors compared between the two stocks.

About Sutro Biopharma

Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.